Loss of GATA6 expression promotes lymphatic metastasis in bladder cancer

Wang, Chanjuan; Liu, Qinghua; Huang, Ming; Zhou, Qianghua; Zhang, Xiaoyu; Zhang, Jingtong; Xie, Ruihui; Yu, Yang; Shang, Chaoqun; Fan, Jian‐Bing; Chen, Zhanghua

doi:10.1096/fj.201903176r

Cited by 18 publications

(13 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…. A final immunoreactivity score (IRS) for each tissue was obtained by plusing the intensity level and the percentage of staining [30]. IRS more than 4 was grouped into high expression of TopBP1.…”

Section: Immunostaining Score Evaluationmentioning

confidence: 99%

Topoisomerase II-binding protein 1 promotes the progression of prostate cancer via ATR-CHK1 signaling pathway

Peng

et al. 2020

Aging

Self Cite

View full text Add to dashboard Cite

DNA damage response (DDR) plays an important role in the progression of cancers, including prostate cancer (PCa). Topoisomerase II-binding protein 1 (TopBP1) is an essential promotor of ATR-mediated DDR. Herein, we investigated the association between TopBP1 and PCa and determined its effect on the progression of PCa. The expression and clinical features of TopBP1 were analyzed using large-scale cohort of tissue microarray analyses and The Cancer Genome Atlas database, which indicated that TopBP1 was positively correlated with high Gleason Score, advanced clinical and pathological stages, the metastasis status. Multivariate analysis revealed that the upregulation of TopBP1 was an independent predictor for a worse biochemical recurrencefree survival (BCR-free survival). Furthermore, we discovered that downregulation of TopBP1 significantly suppressed the growth and migration ability of PCa lines by loss-of-function assays in vitro. Further mechanistic investigations clarified that TopBP1 promoted proliferation and migration by activating ATR-Chk1 signaling pathway.

show abstract

Section: Immunostaining Score Evaluationmentioning

confidence: 99%

Topoisomerase II-binding protein 1 promotes the progression of prostate cancer via ATR-CHK1 signaling pathway

Peng

et al. 2020

Aging

Self Cite

View full text Add to dashboard Cite

show abstract

“…Therefore, further study on the mechanism of progression, recurrence and metastasis of BLCA is the focus of clinical research. 11 A large number of relevant studies have shown that the changes of gene expressions can significantly affect the progression of BLCA, such as transcription factor GATA-binding factor 6 (GATA6), 12 stromal antigen 2 (STAG2), 13 BCL2L2-PABPN1 and CHFR-GOLGA3, 14 growth arrest-specific transcript 5 (GAS5), 15 fibroblast growth factor receptor 3 (FGFR3) 16 and lymph node metastasis associated transcript 1 (LNMAT1). 17 α-E-catenin (CTNNA1) is considered to be an important protein connecting the E-Cadherin/ β-catenin.…”

Section: Introductionmentioning

confidence: 99%

<p>α-E-Catenin (CTNNA1) Inhibits Cell Proliferation, Invasion and EMT of Bladder Cancer</p>

Chi¹,

Xu²,

Song³

et al. 2020

CMAR

View full text Add to dashboard Cite

Aim Bladder cancer (BLCA) is an urogenital system tumor with a high morbidity. We aimed to explore the function and potential mechanism of α-E-catenin (CTNNA1) in BLCA. Methods The CTNNA1 expression in BLCA tissues was detected using qRT-PCR and immunohistochemistry. QRT-PCR and Western blot were performed to measure the CTNNA1 expression in BLCA cell lines. CTNNA1 expression was up-regulated in T24 and UMUC-2 cells by CTNNA1 overexpression plasmid transfection. Cell proliferation, apoptosis, migration and invasion were respectively assessed by CCK-8 assay, flow cytometry, wound healing assay and transwell assay. The expression levels of epithelial–mesenchymal transition (EMT)-related factors were tested by qRT-PCR and Western blot. BLCA nude mice models were constructed to explore the effects of CTNNA1 on BLCA in vivo. Gene set enrichment analysis (GSEA) was proceeded to identify the CTNNA1-related pathways in BLCA. Results The expressions of CTNNA1 were down-regulated in BLCA tissues and cell lines, and its low expression indicated poor prognosis of BLCA patients. CTNNA1 inhibited cell proliferation, migration, invasion and EMT and promoted cell apoptosis in BLCA cells. CTNNA1 enhanced E-cadherin expression and suppressed N-cadherin, snail, MMP2 and MMP9 expressions in BLCA cells, which suggested that CTNNA1 repressed EMT in BLCA cells. Moreover, CTNNA1 could inhibit tumor growth in vivo. CTNNA1 was positively associated with P53 and apoptosis pathways in BLCA cells. Conclusion CTNNA1 inhibited cell proliferation, migration, invasion and EMT and promoted cell apoptosis in BLCA via activating P53 and apoptosis pathways. CTNNA1 might be a novel target in BLCA therapy.

show abstract

“…And the LN invasion was related with the alteration of RHV-BC in gene (TP53 and RB1 mutation), RNA expression (DANCR, Ki67 mRNA), and cellular factors (VEGF-C, CK7). 21,27,28 We had the same conclusion among patients with RHV-BC, but only on the basis of univariable analysis, not multivariable analysis. This was probably due to a limited sample size.…”

Section: Discussionmentioning

confidence: 79%

<p>Clinical Characteristics and Prognosis of Rare Histological Variants of Bladder Cancer: A Single-Center Retrospective Study from China</p>

Li¹,

Li²,

Yang³

et al. 2020

CMAR

View full text Add to dashboard Cite

To investigate the clinical characteristics and prognosis of patients with rare histological variants of bladder cancer (RHV-BC) in China. Materials and Methods: Patients diagnosed as bladder carcinoma with RHV in our center, from March 2009 and April 2019, were included. The univariate and multivariate COX regression model were used to evaluate the association between clinical characteristics and overall survival (OS). Results: A total of 54 (1.4%) patients with RVH-BC were identified from 3803 potential patients with bladder cancer. The RHV classifications included micropapillary variant (MPV), sarcomatoid variant (SAV), neuroendocrine variant (NEV), nested variant (NV), plasmacytoid variant (PCV), and lymphoepithelioma-like variant (LEV), which were found in 19, 18, seven, six, three, and one patient, respectively. The mean of recurrence-free survival (RFS), cancer-specific survival (CSS), and OS of patients were 18.8 months, 37.0 months and 36.0 months, respectively. The multivariable analyses indicated that metastasis and T ≥2 were independent risk factors of OS. Besides, 84.4% (27/32) of patients who were receiving intravesical therapies (IVT) suffered recurrence. Patients with adjuvant chemotherapy (AC) had a recurrence rate of 64.7% (11/17). Conclusion: T≥2 and metastasis were independent risk factors of OS in patients with RHV-BC. Considering a high recurrence following transurethral resection of bladder tumor (TURBT) and IVT, early radical cystectomy (RC) might be performed for patients with RHV-BC.

show abstract

Loss of GATA6 expression promotes lymphatic metastasis in bladder cancer

Cited by 18 publications

References 41 publications

Topoisomerase II-binding protein 1 promotes the progression of prostate cancer via ATR-CHK1 signaling pathway

Topoisomerase II-binding protein 1 promotes the progression of prostate cancer via ATR-CHK1 signaling pathway

<p>α-E-Catenin (CTNNA1) Inhibits Cell Proliferation, Invasion and EMT of Bladder Cancer</p>

<p>Clinical Characteristics and Prognosis of Rare Histological Variants of Bladder Cancer: A Single-Center Retrospective Study from China</p>

Contact Info

Product

Resources

About